SOMAÍ, Bedrocan enter global manufacturing partnership

SOMAÍ has announced a manufacturing partnership with Bedrocan. Under the agreement, Bedrocan will supply its cannabis flower, which SOMAÍ will process into EU-GMP-compliant oral solutions and potentially other extract-based formulations. These products will be developed and commercialized under the Bedrocan brand across international medical cannabis markets.

Bedrocan is recognized for its focus on standardized cannabis production with consistent cannabinoid composition, supporting reproducible therapeutic outcomes.

Through this partnership, SOMAÍ will apply its EU-GMP manufacturing, purification, and formulation capabilities to convert Bedrocan's pharmaceutical raw material into finished dosage forms suitable for prescription use. With this, the proven quality and consistency of Bedrocan's cannabis API, is now extended into new dosage forms. It builds on Bedrocan's established authority and decades-long track record in the medicinal cannabis field, reinforcing the company's reputation for reliability, standardisation, and pharmaceutical-grade manufacturing.

The partnership reflects a shared focus on standardization, quality, and regulatory compliance across the medical cannabis value chain. "Bedrocan has established a global reputation for standardizing its production methods and assuring pharmaceutical-grade cannabis with consistent cannabinoid composition," said George Bellow, Co-Founder of SOMAÍ. "Our role is to translate that consistency into EU-GMP extract formulations that meet the expectations of healthcare professionals and international medical markets." By combining Bedrocan's cannabis as an active pharmaceutical ingredient with SOMAÍ's EU-GMP manufacturing and formulation capabilities, the collaboration supports the development of cannabis-based medicines with reliable dosing, reproducible therapeutic profiles, and consistent patient outcomes.

"SOMAÍ's proven quality standards and expertise in cannabinoid formulation and manufacturing have been key to establishing this relationship. Their rigorous approach to quality and control has been fundamental to how we've been able to manufacture and develop new Bedrocan products," said Jaap Erkelens, CEO of Bedrocan International.